University of Pittsburgh logo

Paul Szabolcs, MD

  • Division Director, Blood and Marrow Transplantation and Cellular Therapies and Professor of Pediatrics and Immunology

Administrative Assistant: Amanda Greygor

Dr. Paul Szabolcs trained at Semmelweis University School of Medicine in Budapest. He completed his residency at Bellevue Hospital/NYU Medical Center and was Chief Fellow at Sloan Kettering Cancer Center in New York City. He completed postdoctoral fellowships at Memorial Sloan Kettering in Molecular Biology and at Rockefeller University in Physiology and Cellular Immunology. He has been the Division Director of Blood and Marrow Transplantation and Cellular Therapies since 2011.

Professional and Scientific Society Memberships

  • American Society of Hematology (ASH), 1995-Present
  • American Society for Blood and Marrow Transplantation (ASBMT), 1998-Present
  • American Association of Immunologists (AAI), 1998-Present
  • Fellow, American Academy of Pediatrics, 1998-Present
  • Center for International Blood and Marrow Transplant Research, 2004-Present
  • International Society for Cellular Therapy (ISCT), 2005-Present
  • Society for Pediatric Research (SPR), Member, 2006-Present
  • Center for International Blood and Marrow Transplant Research, 2009-2014
  • Clinical Immunology Society, 2010-Present
  • University of Pittsburgh Cancer Institute, 2012-Present
  • American Pediatric Society, 2013-Present
  • FOCIS, 2017-Present

Education & Training

  • MD, summa cum laude, Semmelweis University School of Medicine, 1985
  • Residency in Pediatrics, Bellevue Hospital-New York University Medical Center, 1987-1990
  • Research Assistant in Pediatrics, The Hospital of the University of Pennsylvania, 1986-1987
  • Teaching Assistant in Pediatrics, Bellevue Hospital-New York University Medical Center, 1989-1990
  • Fellowship in Pediatric Hematology-Oncology, Cornell University Medical College-New York Hospital, Memorial Sloan-Kettering Cancer Center, 1990-1993
  • Postdoctoral Fellowship, Memorial Sloan-Kettering Cancer Center, 1991-1993
  • Chief Fellow in Pediatric Hematology-Oncology, New York Hospital, Memorial Sloan-Kettering Cancer Center, 1992-1993
  • Special Fellow in Pediatrics, Memorial Sloan-Kettering Cancer Center, 1993-1994
  • Special Laboratory Training, Rockefeller University Department of Cellular Physiology and Immunology, 1994-1997
  • Special Laboratory Training, Duke University Medical Center, Division of Blood and Marrow Transplantation, Department of Pediatrics, 2008-2009

Selected Publications

Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh MB. Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplant. 2014 Aug;49(8):1098-105. Epub 2014 Jun 16. PMID: 24933209 

Szabolcs P, Buckley R, Davis R, Moffet J, Voynow J, Jeyaraj A, Chen X, Sempowski G, Zaas D.  Tolerance After Lung and Bone Marrow Transplantation from an Unrelated Cadaveric Donor.  Journal of Allergy and Clinical Immunology, 2015 Feb;135(2):567-70. Epub 2014 Sep 26, PMID: 25262460

Allewelt H, Martin PL, Szabolcs P, Chao N, Buckley R, Parikh S Hematopoietic stem cell transplantation for CD40 ligand deficiency: Single institution experience. Pediatr Blood Cancer. 2015 Aug 20. doi: 10.1002/pbc.25711. PMID: 26291959

Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JL, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016 Apr;51(4):573-80. doi: 10.1038/bmt.2015.316. PMID: 26726945

Mehta RS, Chen X, Antony J, Boyiadzis M, Szabolcs P. Generating peripheral blood derived lymphocytes reacting against autologous primary AML blasts. Journal of Immunotherapy. 2016;39(2):71-80, PMID: 26849076

Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JA, Auletta J, Komanduri KV, Lindemans C, Riches ML.Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep;22(9):1636-45. doi: 10.1016/j.bbmt.2016.06.012. Epub 2016 Jun 22. PMID:27343716

Goyal RK, Ibrahimova A, Escolar ML, Szabolcs P, Vander Lugt M, Windreich RM, Weiner DJ. Forced deflation pulmonary function test: a novel method to evaluate lung function in infants and young children. Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26356. Epub 2016 Nov 22  PMID: 27873442

Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, Plant AS, Su HC, Allenspach EJ, Slatter M, Abinun M, Lilic D, Cunningham-Rundles C, Eckstein O, Olbrich P, Guillerman RP, Patel NC, Demirdag YY, Zerbe C, Freeman AF, Holland SM, Szabolcs P, Gennery A, Torgerson TR, Milner JD, Leiding JW. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT) or STAT3 mutations. J. Allergy Clin Immunol.2018 Nov. 142(5)-1665-1669. doi: 10.1016/j.jaci.2018.07.020. Epub 2018 Aug 6 PMID:30092289

Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, Small TN, Chaisson J, Dvorak CC, Murnane M, Kapoor N, Abdel-Azim H, Hanson IC, Martinez C, Bleesing JJH, Chandra S, Smith AR, Cavanaugh ME, Jyonouchi S, Sullivan KE, Burroughs L, Skoda-Smith S, Haight AE, Tumlin AG, Quigg TC, Taylor C, Dávila Saldaña BJ, Keller MD, Seroogy CM, Desantes KB, Petrovic A, Leiding JW, Shyr DC, Decaluwe H, Teira P, Gillio AP, Knutsen AP, Moore TB, Kletzel M, Craddock JA, Aquino V, Davis JH, Yu LC, Cuvelier GDE, Bednarski JJ, Goldman FD, Kang EM, Shereck E, Porteus MH, Connelly JA, Fleisher TA, Malech HL, Shearer WT, Szabolcs P, Thakar MS, Vander Lugt MT, Heimall J, Yin Z, Pulsipher MA, Pai SY, Kohn DB, Puck JM, Cowan MJ, O'Reilly RJ, Notarangelo LD. SCID genotype and 6-month posttransplant CD4 count predicts survival and immune recovery. Blood. 2018 Oct 25;132(17):1737-1749. doi: 10.1182/blood-2018-03-840702. Epub 2018 Aug 28 PMID:30154114

Dreyzin A, Michaels MG, Vander Lugt MT, Szabolcs P. Oral ribavirin for paramyxovirus infection after alemtuzumab-containing reduced-intensity conditioning HCT regimen. Pediatr Transplant 2019 Jan 27: e13358. Doi: 10.1111/petr. 13358 EPub PMID:30687992

Vander Lugt MT, Hill M, Escolar M, Chen W, Szabolcs P.” Rapid Reconstitution of Treg Subsets is Associated with Reduced Rates of GvHD and Absence of Viremia after Cord Blood Transplantation in Children with Reduced-Intensity Conditioning Utilizing Alemtuzumab” Cytotherapy 

Full Publication List via NIH PubMed »